Ash Stevens, Inc. (ASI), has received approval from the FDA for its facility in Riverview, MI for the manufacture of the API ixazomib, an oral proteasome inhibitor indicated in combination with leanlidomide and dexamethasone for the treatment of multiple myeloma.   “Ixazomib is a novel, orally active drug, giving hope to certain patients suffering from multiple myeloma,” said Dr. Stephen Munk, chief executive officer and president of Ash Stevens. “The rapid approval by FDA to...